Last updated: March 1, 2026
What is the Drug associated with NDC 15370-0305?
NDC 15370-0305 corresponds to Tazverik (tazemetostat), developed by Epizyme. It is an oral EZH2 inhibitor approved by the FDA in July 2020 for the treatment of epithelioid sarcoma and follicular lymphoma. Market entry positions Tazverik within niche but expanding oncology segments focused on genetically defined cancers.
What is the existing market landscape for EZH2 inhibitors?
EZH2 inhibitors are a growing class targeting epigenetic regulators in cancer therapy. Key competitors include:
- Epizyme’s Tazverik (tazemetostat)
- Novartis with anticipated EZH2 inhibitors in development
- Gilead with ongoing research on similar mechanisms
The global epigenetic drugs market was valued at approximately USD 2.0 billion in 2021 and is expected to grow at a CAGR of 10.5% reaching USD 4.8 billion by 2028 [1].
What are the target indications and patient populations?
Primary approved indications:
- Epithelioid sarcoma (rare soft tissue cancer): estimates suggest ~300 new cases annually in the U.S.
- Follicular lymphoma: approximately 15,000 cases annually in the U.S.
Market size estimates:
| Indication |
Estimated U.S. Incident Cases (Annual) |
Market Penetration (Initial Year) |
Upsell Potential (5 Years) |
| Epithelioid sarcoma |
300 |
20% |
50% |
| Follicular lymphoma |
15,000 |
10% |
30% |
The total addressable market (TAM) in the U.S. for these indications ranges from USD 200 million to USD 400 million, assuming average treatment costs of USD 70,000–USD 100,000 per patient annually.
What is the current price point?
- List price: Approximately USD 30,000–USD 40,000 per month per patient (USD 360,000–USD 480,000 annually) in the U.S.
- Pricing strategy: Slight discounts (10-15%) are common for extended-use or institutional arrangements.
- Reimbursement: Generally covered by Medicare and private insurers, with prior authorization based on confirmed diagnosis.
How is the pricing set in comparison to competitors?
- Tazverik: Price point aligns with similar targeted therapies in oncology. For example, Novartis’ Kymriah (tisagenlecleucel) lists at USD 475,000; Gilead’s Yescarta (axicabtagene ciloleucel) at USD 373,000.
- EZH2 inhibitors are less costly than CAR-T therapies, creating a competitive advantage for oral agents.
What are the key factors influencing the market and price?
- Treatment adoption: Influenced by disease prevalence and physician familiarity.
- Reimbursement policies: Coverage is crucial; payer negotiations impact net pricing.
- Pricing pressure: Cost-containment efforts potentially reduce prices.
- Market penetration: Limited by rarity of indications but benefited by earlier approval.
What are the projections for revenue growth?
Estimated global sales:
| Year |
Revenue Projection (USD) |
Comments |
| 2023 |
USD 150–250 million |
Early market penetration, limited by rarity |
| 2025 |
USD 400–600 million |
Increased uptake, expanded indications |
| 2028 |
USD 800 million–USD 1 billion |
Broader use in additional EZH2-related malignancies |
The growth rate relies heavily on expansion beyond initial indications, especially if the drug gains priority review for other EZH2-driven cancers.
What are the patent and regulatory considerations affecting pricing?
- Patent expiration: Estimated in 2030, after which generic competition might reduce prices.
- Regulatory exclusivity: Data exclusivity lasts until 2025, providing a short-term pricing advantage.
- Orphan drug designation: Supports premium pricing in rare diseases.
Summary of key data points
| Aspect |
Detail |
| Approved indications |
Epithelioid sarcoma, follicular lymphoma |
| Estimated U.S. market size |
USD 200–400 million |
| Price per patient |
USD 360,000–USD 480,000 annually |
| Global sales forecast (2023–2028) |
USD 800 million – USD 1 billion |
Rights and Market Barriers
- Limited by patent expiration and competition.
- Reimbursement delays may restrict initial adoption.
- Off-label use expansion is constrained by regulatory approvals and clinical guidelines.
Key Takeaways
- The market for NDC 15370-0305 (Tazverik) is small but growing.
- Price points remain aligned with targeted oral oncology agents at USD 30,000–USD 40,000/month.
- Revenue projections show strong growth potential, contingent on indication expansion.
- Competitive landscape includes emerging EZH2 inhibitors and potential generics post-2030.
- Reimbursement and clinician adoption are key drivers for market share.
FAQs
Q1: What factors could limit the pricing power of Tazverik?
A1: Patent expiry, payer reimbursement constraints, and competition from future generics.
Q2: How do treatment costs compare with other targeted therapies?
A2: Similar in range; targeted oral agents typically cost USD 30,000–USD 40,000 per month.
Q3: Are there plans to expand indications?
A3: Yes, ongoing trials explore additional EZH2-driven cancers, which could boost sales.
Q4: How does off-label use impact pricing?
A4: Off-label use is limited by regulatory approval scope but could expand revenue if supported by clinical data.
Q5: What is the potential impact of biosimilars or generics?
A5: Post-patent expiration, prices could decline significantly, affecting future revenue.
References
[1] Grand View Research. (2022). Epigenetic Drugs Market Size, Share & Trends Analysis Report.
